VYNE
VYNE
NASDAQ · Pharmaceuticals

Vyne Therapeutics Inc

$13.69
-1.22 (-8.18%)
As of Nov 7, 2:45 AM ET ·
Financial Highlights (FY 2026)
Revenue
4.55M
Net Income
-211,449,798
Gross Margin
—
Profit Margin
-4,646.1%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — 93.4% 36.5% 36.5%
Operating Margin -5,219.1% -4,697.2% 24.1% 26.2%
Profit Margin -4,646.1% -4,413.8% 22.3% 17.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 4.55M 28.2K 2.72M 3.05M
Gross Profit — 26.3K 990.9K 1.11M
Operating Income -237,531,754 -1,324,709 655.4K 797.6K
Net Income -211,449,798 -1,181,711 604.8K 522.0K
Gross Margin — 93.4% 36.5% 36.5%
Operating Margin -5,219.1% -4,697.2% 24.1% 26.2%
Profit Margin -4,646.1% -4,413.8% 22.3% 17.1%
Rev Growth — +5.9% -5.6% +23.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 5.81M 7.24M
Total Equity — — 10.77M 11.64M
D/E Ratio — — 0.54 0.62
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -237,343,199 -1,400,261 831.2K 1.01M
Free Cash Flow — — 485.0K 536.6K